IMI at BIO 2018Start Date 04/06/2018 End Date 07/06/2018
IMI took part in the 2018 BIO International Convention which was held in Boston, US on 4-7 June inclusive.
IMI session: ‘Will public-private partnerships take the leap into open science?’
Tuesday 5 June, 11:00 | Room 252AB, Level 2 | Session ID 19842
IMI organised a session in the Business Development & Finance track of the BIO education programme. The past decade has seen a revolution in the way we drive science, tackle research and development (R&D) bottlenecks, and deliver breakthroughs – giving rise to large-scale public-private partnerships (PPPs) tackling major global health challenges. PPPs have made a name for themselves in the open innovation landscape, translating research results and scientific knowledge into transformative outcomes. Looking to the future of public-private collaborations, the spotlight shifts towards open science, intended as earlier, wider and shared access to research data and knowledge generated. PPPs now face a tremendous opportunity, but will they be able to ride the momentum? This session brought together world-class initiatives leading a profound transformation in the global research landscape. Discussions addressed the need for a FAIR (findable, accessible, interoperable, reusable) approach to data; dynamic intellectual property and publication strategies; and the value of open science for industry and society.
Presentations and speakers' profiles
Pierre Meulien, Executive Director, Innovative Medicines Initiative (IMI)
- Open science - a pharmaceutical industry perspective
Carlo Incerti, Sr Vice President, Head of Global Medical Affairs, Sanofi Genzyme
- Open science, public-private partnerships, and the NIH
David Wholley, Senior Vice-President, Research Partnerships, Foundation for the National Institutes of Health (FNIH)
- Global health, open innovation and access
Shyam Bishen, US Regional Director, Life Sciences Partnerships, Global Health Bill & Melinda Gates Foundation
- Never mind the gap
Nikolay Savchuk, Managing Director, Torrey Pines Investment
View IMI's Twitter moment on the session.
Session: ‘The value of vaccines in AMR’
Wednesday 6 June, 13:45 | Room 251, Level 2 | Session ID 36185
IMI Executive Director Pierre Meulien was a speaker in this session, which is part of the Infectious Diseases and Vaccines track of the education programme. Vaccines are a key tool for addressing antimicrobial resistance (AMR), both by preventing bacterial infections and reducing the use of antimicrobials. The full value of vaccines has not been realised due to regulatory, behavioural, and economic challenges. This session discussed the immense potential and value of vaccines in addressing antimicrobial resistance, the challenges that preclude the availability and uptake of vaccines, and measures that could promote the development and deployment of vaccines as part of a comprehensive strategy to address AMR.
- View Pierre Meulien's presentation
- Read Pierre Meulien's article 'Public-private partnerships provide hope in the fight against AMR' , published in the BIO BUZZ magazine on Thursday 7 June.
IMI at the exhibition
IMI was also present at the European Commission’s booth (no. 1943) at the BIO Exhibition. There were people on hand throughout the event to answer questions about IMI as well as the European Commission’s wider research programmes.
- Download the leaflet on IMI handed out at the stand
- Meet the organisations and people present at the booth in this brochure
The BIO International Convention (BIO) 2018 attracted over 18 000 people from over 7 000 organisations in 67 countries. The programme included a strong educational programme with over 180 sessions addressing cutting-edge issues in a wide spectrum of life science and application areas. The event exhibition featured over 1 800 exhibitors including several international pavilions.
Event website: http://convention.bio.org/